Estrogen Receptor Signaling And Crosstalk With The Ah Receptor In Endometrial Cancer Cells

Common risk factors for the development of endometrial and breast cancer include early menarche, late menopause, null parity, and later age at first birth, indicating that "lifetime" exposure to estrogens increases the incidence of both tumors. In contrast, smoking protects against the development of endometrial cancer, whereas the role of smoking in breast cancer incidence is equivocal and maybe dependent on the timing and duration of smoking. Constituents of cigarette smoke bind and activate the aryl hydrocarbon receptor (AhR), and research in this laboratory has focused on characterizing the inhibitory AhR-estrogen receptor (ER) alpha crosstalk in endometrial and breast cancer cell lines. Both Ishikawa and ECC1 endometrial cancer cells express the AhR and ERalpha. proteins by Western blot analysis. Moreover, AhR ligands such as benzo[a]pyrene (BaP) and/or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induce CYP1Al-dependent activity or reporter gene activity in cells transfected with constructs containing dioxin-responsive elements as promoters. Estrogen responsiveness was also confirmed in these cells, as evidenced by gene/reporter gene assay and the induction of cell proliferation by 17beta-estradiol (E2). Inhibitory AhR-ERalpha crosstalk studies have shown that TCDD and/or BaP inhibit E2-induced growth of endometrial cancer cells and also block hormone-activated reporter gene/gene responses. Although there are several possible mechanisms for the interaction between AhR and ERalpha signaling pathways, the role of AhR-mediated down-regulation of ERalpha will be discussed as one possible mechanism. In addition, selective AhR modulators have been developed for the treatment of breast and endometrial cancer and the potential use of these compounds alone or in combination with tamoxifen will be outlined.